ANTX logo

AN2 Therapeutics, Inc.

ANTX
Healthcare|Biotechnology|US
$4.00
+0.04 (+1.14%)
DCF Value
$0.59
Tangible Book / Share
$1.70
Cash / Share
$1.75
Next Earnings Report
Mar 31, 2027
EPS est. -$0.23
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Apr 20, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (1)

Dec 2027
Est. completion
P2Mycobacterium Abscessus Infection
Epetraborole in Patients With Mycobacterium Abscessus Lung Disease
NCT07301320n=84

Recent Press Releases

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
Nov 4, 2026 · Business Wire
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
Nov 2, 2026 · Business Wire
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Oct 23, 2026 · Business Wire
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
Oct 21, 2026 · Business Wire
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Oct 20, 2026 · Business Wire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
Oct 12, 2026 · PRNewsWire
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Sep 28, 2026 · Business Wire
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
Sep 16, 2026 · Business Wire
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Aug 31, 2026 · Business Wire
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
Aug 24, 2026 · Business Wire

SEC Filings (61)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 14, 2026S-8Employee stock planDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Jun 9, 20268-KMaterial eventDocumentIndex
Jun 4, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
Apr 22, 2026ARSAnnual report to holdersDocumentIndex
Apr 22, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 22, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 20, 2026EFFECTDocumentIndex
Apr 20, 2026424B3Offering prospectusDocumentIndex
Apr 20, 2026424B5Offering prospectusDocumentIndex
Apr 9, 2026S-3Shelf registrationDocumentIndex
Apr 9, 20268-KMaterial eventDocumentIndex
Mar 25, 2026DDocumentIndex
Mar 20, 20268-KMaterial eventDocumentIndex
Mar 17, 2026S-8Employee stock planDocumentIndex
Mar 17, 202610-KAnnual reportDocumentIndex
Mar 17, 20268-KMaterial eventDocumentIndex
Mar 16, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 10, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 29, 20268-KMaterial eventDocumentIndex
Nov 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Aug 12, 202510-QQuarterly reportDocumentIndex
Aug 12, 20258-KMaterial eventDocumentIndex
Jun 20, 20258-KMaterial eventDocumentIndex
Jun 18, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Jun 11, 20258-KMaterial eventDocumentIndex
Jun 4, 2025SC 13GPassive 5%+ stakeDocumentIndex
May 30, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
May 27, 20258-KMaterial eventDocumentIndex
May 13, 202510-QQuarterly reportDocumentIndex